{"title":"Females with X-Linked Muscle Disorders: an underestimated patient population.","authors":"Luisa Politano","doi":"10.36185/2532-1900-1096","DOIUrl":null,"url":null,"abstract":"<p><p>Carriers of genetic diseases including female carriers of X-linked disorders are traditionally believed to be asymptomatic due to the compensatory presence of the unmutated gene on the other allele. However, in recent decades numerous contributions have appeared in the literature showing how females carrying X-linked diseases can also present signs and symptoms linked to the specific gene defect. To explain the clinical manifestations observed in female carriers, several mechanisms leading to a reduced protein expression have been hypothesized, in particular the role of the X-chromosome inactivation (XCI). In this review, the focus will be on the relationship between skewed XCI and the development of muscle or cardiac symptoms in female carriers of the most frequent types of muscle disorders such as Duchenne and Becker muscular dystrophies, Emery-Dreifuss muscular dystrophy and Myotubular Myopathy. In all cases, there is a tendency for females with a more severe phenotype to have a skewed pattern of XCI, while females with an intermediate phenotype have a random pattern. Given the increasing recognition of important clinical presentations in females with X-linked muscle disorders and the recent availability of causal therapies for these diseases, specific guidelines are desirable and recommended that allow women to be properly recognized and have access to appropriate therapies.</p>","PeriodicalId":93851,"journal":{"name":"Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology","volume":"44 1","pages":"33-36"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36185/2532-1900-1096","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
遗传病的携带者,包括 X 连锁遗传病的女性携带者,传统上被认为是无症状的,因为另一个等位基因上的未突变基因具有代偿性。然而,近几十年来,大量文献表明,X 连锁遗传病女性携带者也会出现与特定基因缺陷有关的体征和症状。为了解释在女性携带者身上观察到的临床表现,人们假设了几种导致蛋白质表达减少的机制,特别是 X 染色体失活(XCI)的作用。在这篇综述中,重点将放在偏斜的 XCI 与最常见类型肌肉疾病(如杜氏和贝克型肌营养不良症、艾默里-德赖福斯肌营养不良症和肌管肌病)的女性携带者出现肌肉或心脏症状之间的关系上。在所有病例中,表型较严重的女性往往具有偏斜的 XCI 模式,而表型居中的女性则具有随机模式。鉴于人们日益认识到女性 X 连锁肌肉疾病患者的重要临床表现,而且最近出现了治疗这些疾病的因果疗法,因此需要并建议制定具体的指南,以便正确认识女性 X 连锁肌肉疾病患者,并为她们提供适当的治疗。
Females with X-Linked Muscle Disorders: an underestimated patient population.
Carriers of genetic diseases including female carriers of X-linked disorders are traditionally believed to be asymptomatic due to the compensatory presence of the unmutated gene on the other allele. However, in recent decades numerous contributions have appeared in the literature showing how females carrying X-linked diseases can also present signs and symptoms linked to the specific gene defect. To explain the clinical manifestations observed in female carriers, several mechanisms leading to a reduced protein expression have been hypothesized, in particular the role of the X-chromosome inactivation (XCI). In this review, the focus will be on the relationship between skewed XCI and the development of muscle or cardiac symptoms in female carriers of the most frequent types of muscle disorders such as Duchenne and Becker muscular dystrophies, Emery-Dreifuss muscular dystrophy and Myotubular Myopathy. In all cases, there is a tendency for females with a more severe phenotype to have a skewed pattern of XCI, while females with an intermediate phenotype have a random pattern. Given the increasing recognition of important clinical presentations in females with X-linked muscle disorders and the recent availability of causal therapies for these diseases, specific guidelines are desirable and recommended that allow women to be properly recognized and have access to appropriate therapies.